anastrozole has been researched along with Cancer of Ovary in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 5.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "A subset of patients with estrogen- or progesterone-positive platinum-resistant or platinum-refractory recurrent epithelial ovarian cancers derives clinical benefit from anastrozole, with acceptable toxicity." | 5.24 | Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. ( Beale, PJ; Bonaventura, A; DeFazio, A; Friedlander, ML; Goh, JCH; Grant, PT; Hadley, AM; Mapagu, C; Martyn, J; McNally, OM; Mileshkin, LR; OʼConnell, RL; Scurry, J; Sjoquist, KM, 2017) |
| "Anastrozole was well-tolerated." | 2.90 | PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; Davis, A; deFazio, A; Friedlander, M; Goh, J; Grant, P; Kennedy, CJ; McNally, O; Mileshkin, L; Moujaber, T; O'Connell, RL; Scurry, J; Sjoquist, KM; Sykes, P; Tan, K; Tang, M, 2019) |
| "Anastrozole was well tolerated." | 2.90 | PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; DeFazio, A; Friedlander, M; Goh, J; Grant, P; Kok, PS; Mapagu, C; O'Connell, RL; Scurry, J; Sjoquist, K, 2019) |
| "After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled." | 1.72 | [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report]. ( Fukino, S; Hamasaki, T; Kodama, W; Nishimura, K; Oota, R; Suo, K; Takagi, Y; Tanaka, Y, 2022) |
| "Letrozole was administered post operatively in 55." | 1.46 | Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? ( Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G, 2017) |
| "Blepharitis was noted in 68 of 82 eyes (73%), decreased or poor tear function in 24 eyes (29%), conjunctival injection in 18 eyes (22%) and superficial punctate keratitis in 12 eyes (29%)." | 1.39 | Dry eye syndrome in aromatase inhibitor users. ( Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K, 2013) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 1.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, Y | 3 |
| Oota, R | 3 |
| Takagi, Y | 3 |
| Kodama, W | 3 |
| Nishimura, K | 3 |
| Hamasaki, T | 3 |
| Fukino, S | 3 |
| Suo, K | 3 |
| Quesada, S | 3 |
| Bini, M | 3 |
| Lebreton, C | 3 |
| Ray-Coquard, I | 3 |
| Banerjee, SN | 1 |
| Tang, M | 2 |
| O'Connell, RL | 3 |
| Sjoquist, K | 2 |
| Clamp, AR | 1 |
| Millan, D | 1 |
| Nottley, S | 1 |
| Lord, R | 1 |
| Mullassery, VM | 1 |
| Hall, M | 1 |
| Gourley, C | 2 |
| Bonaventura, T | 3 |
| Goh, JC | 1 |
| Sykes, P | 2 |
| Grant, PT | 2 |
| McNally, O | 2 |
| Alexander, L | 1 |
| Kelly, C | 1 |
| Carty, K | 1 |
| Divers, L | 1 |
| Bradshaw, N | 1 |
| Edmondson, RJ | 1 |
| Friedlander, M | 3 |
| Bonaventura, A | 1 |
| OʼConnell, RL | 1 |
| Mapagu, C | 2 |
| Beale, PJ | 1 |
| McNally, OM | 1 |
| Mileshkin, LR | 1 |
| Hadley, AM | 1 |
| Goh, JCH | 1 |
| Sjoquist, KM | 2 |
| Martyn, J | 1 |
| DeFazio, A | 3 |
| Scurry, J | 3 |
| Friedlander, ML | 1 |
| Fader, AN | 1 |
| Bergstrom, J | 1 |
| Jernigan, A | 1 |
| Tanner, EJ | 1 |
| Roche, KL | 1 |
| Stone, RL | 1 |
| Levinson, KL | 1 |
| Ricci, S | 1 |
| Wethingon, S | 1 |
| Wang, TL | 1 |
| Shih, IM | 1 |
| Yang, B | 1 |
| Zhang, G | 1 |
| Armstrong, DK | 1 |
| Gaillard, S | 1 |
| Michener, C | 1 |
| DeBernardo, R | 1 |
| Rose, PG | 1 |
| Amant, F | 2 |
| Beale, P | 2 |
| Grant, P | 2 |
| Davis, A | 1 |
| Mileshkin, L | 1 |
| Moujaber, T | 1 |
| Kennedy, CJ | 1 |
| Tan, K | 1 |
| Antill, Y | 2 |
| Goh, J | 2 |
| Kok, PS | 1 |
| Deval, B | 1 |
| Rousset, P | 1 |
| Bigenwald, C | 1 |
| Nogales, FF | 1 |
| Alexandre, J | 1 |
| Esfahani, K | 1 |
| Ferrario, C | 1 |
| Le, P | 1 |
| Panasci, L | 1 |
| van Meurs, HS | 1 |
| van der Velden, J | 1 |
| Buist, MR | 1 |
| van Driel, WJ | 1 |
| Kenter, GG | 1 |
| van Lonkhuijzen, LR | 1 |
| Gershenson, DM | 1 |
| Bodurka, DC | 1 |
| Coleman, RL | 1 |
| Lu, KH | 1 |
| Malpica, A | 1 |
| Sun, CC | 1 |
| Korach, J | 1 |
| Perri, T | 1 |
| Beiner, M | 1 |
| Davidzon, T | 1 |
| Fridman, E | 1 |
| Ben-Baruch, G | 1 |
| Blinman, P | 1 |
| Tattersall, MH | 1 |
| Abdul Munem, A | 1 |
| Al-Bahrani, B | 1 |
| Mehdi, I | 1 |
| Kamona, A | 1 |
| Nadas, AM | 1 |
| Turaka, K | 1 |
| Nottage, JM | 1 |
| Hammersmith, KM | 1 |
| Nagra, PK | 1 |
| Rapuano, CJ | 1 |
| del Carmen, MG | 1 |
| Fuller, AF | 1 |
| Matulonis, U | 1 |
| Horick, NK | 1 |
| Goodman, A | 1 |
| Duska, LR | 1 |
| Penson, R | 1 |
| Campos, S | 1 |
| Roche, M | 1 |
| Seiden, MV | 1 |
| Rao, GG | 1 |
| Miller, DS | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Tanaka, T | 1 |
| Murata, T | 1 |
| Kamimura, K | 1 |
| Deguchi, Y | 1 |
| Nonogaki, H | 1 |
| Yasumizu, R | 1 |
| Freeman, SA | 1 |
| Modesitt, SC | 1 |
3 reviews available for anastrozole and Cancer of Ovary
| Article | Year |
|---|---|
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Update on new treatments for rare ovarian tumours.
Topics: Anastrozole; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Paclitaxel; Precision Me | 2023 |
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Topics: Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recur | 2012 |
Clinical applications of hormonal therapy in ovarian cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Dose-Response Rela | 2005 |
5 trials available for anastrozole and Cancer of Ovary
| Article | Year |
|---|---|
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Topics: Adult; Aged; Anastrozole; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recurrence, Lo | 2021 |
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epi | 2017 |
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Cystadenoc | 2019 |
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; CA- | 2019 |
Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Fallopian Tube Neoplasms; Fem | 2003 |
12 other studies available for anastrozole and Cancer of Ovary
| Article | Year |
|---|---|
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2017 |
Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive.
Topics: Anastrozole; Aromatase; Estrogens; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pa | 2019 |
Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor.
Topics: Anastrozole; Aromatase Inhibitors; Ependymoma; Female; Humans; Middle Aged; Nitriles; Ovarian Neopla | 2014 |
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Female; Humans; | 2014 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuv | 2015 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2017 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Mid | 2009 |
A case of uterine tumour resembling ovarian sex cord tumour responding to second-line, single agent anastrazole.
Topics: Anastrozole; Diagnosis, Differential; Female; Humans; Middle Aged; Nitriles; Ovarian Neoplasms; Tria | 2009 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Hu | 2006 |